摘要
目的评价辛伐他汀联合通脉颗粒治疗不稳定型心绞痛的临床疗效及安全性。方法将132例不稳定型心绞痛患者随机分为对照组66例和试验组66例。对照组予以口服辛伐他汀10-40 mg,qd;试验组在对照组的基础上,联合口服通脉颗粒10 mg,tid。2组患者均治疗4周。比较2组患者的临床疗效、心绞痛发作频率、持续时间、血流动力学和血脂指标,以及不良反应发生率。结果治疗后,试验组的总有效率93.94%显著高于对照组的84.85%（P〈0.05）。试验组的心绞痛发作频率、持续时间均明显低于对照组（P〈0.05）。试验组的红细胞压积、全血黏度、纤维蛋白原、总胆固醇、低密度脂蛋白胆固醇水平均显著低于对照组（P〈0.05）。2组患者不良反应发生率比较差异无统计学意义（P〉0.05）。结论辛伐他汀联合通脉颗粒治疗不稳定型心绞痛可有效地缓解患者的临床症状,提高临床疗效,活血化瘀,改善血脂。
Objective To evaluate the clinical efficacy and safety of simvastatin combined with tongmai particle in the treatment of unstable angina. Methods The 132 cases of unstable angina were randomly divided into control group（n = 66） and treatment group（n = 66）. Control group was orally received simvastatin 10-40 mg,qd. Treatment group was oral given tongmai particle 10 mg,tid on the basis of control group.The course of two groups lasted for 4 weeks. The clinical efficacy,angina frequency,duration,hemodynamics and serum lipids,and incidence of adverse drug reactions were compared between two groups. Results After treatment,the clinical efficacy in treatment group was significantly higher than that in control group（93. 94% vs 84. 85%,P〈0. 05）. The attack frequency and duration of angina,levels of hematocrit,whole blood viscosity,fibrinogen,total cholesterol,low-density lipoprotein cholesterol in treatment group were significantly lower than those in control group（P〈0. 05）. The incidence of adverse drug reactions had no significant difference between two groups（P〉0. 05）. Conclusion Simvastatin combined with tongmai particle has a definitive clinical efficacy for the treatment of unstable angina,which can effectively alleviate the clinical symptoms,improve blood circulation and blood lipids.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2016年第8期690-692,共3页
The Chinese Journal of Clinical Pharmacology
基金
2011年河北省医学适用技术跟踪项目基金资助项目(GL2011-89)
